The Effect of Protease-Activated Receptor-1 (PAR-1) Inhibition on Endothelial-Related Biomarkers in Patients with Coronary Artery Disease

Abstract

Background Vorapaxar has been shown to reduce cardiovascular mortality in post-myocardial infarction (MI) patients. Pharmacodynamic biomarker research related to protease-activated receptor-1 (PAR-1) inhibition with vorapaxar in humans has short follow-up (FU) duration and is mainly focused on platelets rather than endothelial cells.

Aim This article assesses systemic changes in endothelial-related biomarkers during vorapaxar treatment compared with placebo at 30 days' FU and beyond, in patients with coronary heart disease.

Methods Local substudy patients in Norway were included consecutively from two randomized controlled trials; post-MI subjects from TRA2P-TIMI 50 and non-ST-segment elevation MI (NSTEMI) patients from TRACER. Aliquots of citrated blood were stored at –80°C. Angiopoietin-2, angiopoietin-like 4, vascular endothelial growth factor, intercellular adhesion molecule-1, vascular cell adhesion molecule-1, E-selectin, von Willebrand factor, thrombomodulin, and plasminogen activator inhibitor-1 and -2 were measured at 1-month FU and at study completion (median 2.3 years for pooled patients).

Results A total of 265 consecutive patients (age median 62.0, males 83%) were included. Biomarkers were available at both FUs in 221 subjects. In the total population, angiopoietin-2 increased in patients on vorapaxar as compared with placebo at 1-month FU (p = 0.034). Angiopoietin-like 4 increased (p = 0.028) and plasminogen activator inhibitor-2 decreased (p = 0.025) in favor of vorapaxar at final FU. In post-MI subjects, a short-term increase in E-selectin favoring vorapaxar was observed, p = 0.029. Also, a short-term increase in von Willebrand factor (p = 0.032) favoring vorapaxar was noted in NSTEMI patients.

Conclusion Significant endothelial biomarker changes during PAR-1 inhibition were observed in post-MI and NSTEMI patients.

Keywords

PAR-1 inhibition - vorapaxar - myocardial infarction (MI) - post-MI - NSTEMI - biomarkers - endothelium

Ethical Statement

This study was approved by the Ethics Committee of Northern Norway and the biobank was licensed by the Ethics Committee of South-Eastern Norway. Biobank no. 10104, ref. 2009/330.

Publikationsverlauf

Eingereicht: 04. Juli 2022

Angenommen: 20. Oktober 2022

Artikel online veröffentlicht:
31. Dezember 2022

• References

• 1 Vu T-KH, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64 (06) 1057-1068
• 2 O'Brien PJ, Molino M, Kahn M, Brass LF. Protease activated receptors: theme and variations. Oncogene 2001; 20 (13) 1570-1581
• 3 Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005; 3 (08) 1800-1814
• 4 Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 2005; 105 (08) 3178-3184
• 5 Gieseler F, Ungefroren H, Settmacher U, Hollenberg MD, Kaufmann R. Proteinase-activated receptors (PARs) - focus on receptor-receptor-interactions and their physiological and pathophysiological impact. Cell Commun Signal 2013; 11: 86
• 6 Ten Cate H, Guzik TJ, Eikelboom J, Spronk HMH. Pleiotropic actions of factor Xa inhibition in cardiovascular prevention: mechanistic insights and implications for anti-thrombotic treatment. Cardiovasc Res 2021; 117 (09) 2030-2044
• 7 Chackalamannil S, Wang Y, Greenlee WJ. et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem 2008; 51 (11) 3061-3064
• 8 Morrow DA, Braunwald E, Bonaca MP. et al; TRA 2P–TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366 (15) 1404-1413
• 9 Tricoci P, Huang Z, Held C. et al; TRACER Investigators. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012; 366 (01) 20-33
• 10 Storey RF, Kotha J, Smyth SS. et al. Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST elevation acute coronary syndromes. Thromb Haemost 2014; 11: 883-891
• 11 Lee KW, Lip GYH, Blann AD. Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor tie-2, and vascular endothelial growth factor levels in acute coronary syndromes. Circulation 2004; 110 (16) 2355-2360
• 12 Boncela J, Przygodzka P, Papiewska-Pajak I, Wyroba E, Cierniewski CS. Association of plasminogen activator inhibitor type 2 (PAI-2) with proteasome within endothelial cells activated with inflammatory stimuli. J Biol Chem 2011; 286 (50) 43164-43171
• 13 Saharinen P, Eklund L, Alitalo K. Therapeutic targeting of the angiopoietin-TIE pathway. Nat Rev Drug Discov 2017; 16 (09) 635-661
• 14 Akwii RG, Sajib MS, Zahra FT, Mikelis CM. Role of angiopoietin-2 in vascular physiology and pathophysiology. Cells 2019; 8 (05) 471
• 15 Guo L, Li S-Y, Ji F-Y. et al. Role of Angptl4 in vascular permeability and inflammation. Inflamm Res 2014; 63 (01) 13-22
• 16 Mattijssen F, Kersten S. Regulation of triglyceride metabolism by Angiopoietin-like proteins. Biochim Biophys Acta 2012; 1821 (05) 782-789
• 17 Georgiadi A, Wang Y, Stienstra R. et al. Overexpression of angiopoietin-like protein 4 protects against atherosclerosis development. Arterioscler Thromb Vasc Biol 2013; 33 (07) 1529-1537
• 18 Xu L, Guo ZN, Yang Y. et al. Angiopoietin-like 4: a double-edged sword in atherosclerosis and ischemic stroke?. Exp Neurol 2015; 272 (272) 61-66
• 19 Rondaij MG, Bierings R, Kragt A, van Mourik JA, Voorberg J. Dynamics and plasticity of Weibel-Palade bodies in endothelial cells. Arterioscler Thromb Vasc Biol 2006; 26 (05) 1002-1007
• 20 Medcalf RL. Plasminogen activator inhibitor type 2: still an enigmatic serpin but a model for gene regulation. Methods Enzymol 2011; 499: 105-134
• 21 Thomas M, Augustin HG. The role of the angiopoietins in vascular morphogenesis. Angiogenesis 2009; 12 (02) 125-137
• 22 Eklund L, Kangas J, Saharinen P. Angiopoietin-Tie signalling in the cardiovascular and lymphatic systems. Clin Sci (Lond) 2017; 131 (01) 87-103
• 23 Aarsetøy R, Ueland T, Aukrust P. et al. Angiopoietin-2 and angiopoietin-like 4 protein provide prognostic information in patients with suspected acute coronary syndrome. J Intern Med 2021; 290 (04) 894-909
• 24 Iglesias MJ, Kruse LD, Sanchez-Rivera L. et al. Identification of endothelial proteins in plasma associated with cardiovascular risk factors. Arterioscler Thromb Vasc Biol 2021; 41 (12) 2990-3004
• 25 Olshan DS, Rader DJ. Angiopoietin-like protein 4: a therapeutic target for triglycerides and coronary disease?. J Clin Lipidol 2018; 12 (03) 583-587
• 26 Le Jan S, Amy C, Cazes A. et al. Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma. Am J Pathol 2003; 162 (05) 1521-1528
• 27 Cazes A, Galaup A, Chomel C. et al. Extracellular matrix-bound angiopoietin-like 4 inhibits endothelial cell adhesion, migration, and sprouting and alters actin cytoskeleton. Circ Res 2006; 99 (11) 1207-1215
• 28 Dijk W, Kersten S. Regulation of lipoprotein lipase by Angptl4. Trends Endocrinol Metab 2014; 25 (03) 146-155
• 29 Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci U S A 2002; 99 (17) 11205-11210
• 30 Bevilacqua MP, Nelson RM. Selectins. J Clin Invest 1993; 91 (02) 379-387
• 31 Macías C, Villaescusa R, del Valle L. et al. Endothelial adhesion molecules ICAM-1, VCAM-1 and E-selectin in patients with acute coronary syndrome [in Spanish]. Rev Esp Cardiol 2003; 56 (02) 137-144
• 32 Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci U S A 1981; 78 (04) 2249-2252
• 33 Boffa MC, Karmochkine M. Thrombomodulin: an overview and potential implications in vascular disorders. Lupus 1998; 7 (Suppl. 02) S120-S125
• 34 Ben Shimon M, Lenz M, Ikenberg B. et al. Thrombin regulation of synaptic transmission and plasticity: implications for health and disease. Front Cell Neurosci 2015; 9: 151
• 35 Peyvandi F, Garagiola I, Baronciani L. Role of von Willebrand factor in the haemostasis. Blood Transfus 2011; 9 (Suppl. 02) s3-s8
• 36 Vaughan DE. PAI-1 and atherothrombosis. J Thromb Haemost 2005; 3 (08) 1879-1883
• 37 Ritchie H, Jamieson A, Booth NA. Regulation, location and activity of plasminogen activator inhibitor 2 (PAI-2) in peripheral blood monocytes, macrophages and foam cells. Thromb Haemost 1997; 77 (06) 1168-1173
• 38 Colognato R, Slupsky JR, Jendrach M, Burysek L, Syrovets T, Simmet T. Differential expression and regulation of protease-activated receptors in human peripheral monocytes and monocyte-derived antigen-presenting cells. Blood 2003; 102 (07) 2645-2652